· Alkem aims to expand access to treatment with its
affordable pertuzumab biosimilar that meets global standards and is backed by
trusted science
Mumbai, September 22, 2025: Alkem Laboratories Ltd. (BSE: 539523,
NSE: ALKEM, “Alkem” and its subsidiaries) today announced the launch of Pertuza
injection 420mg/14mL, a pertuzumab biosimilar, in India for the treatment of
HER2-positive breast cancer.
Alkem’s Pertuza is an affordable, indigenously-developed
and manufactured biosimilar of pertuzumab. In the pivotal phase 3 clinical
trial, Alkem’s pertuzumab biosimilar, developed by its biotech subsidiary,
demonstrated equivalence in efficacy, safety, and immunogenicity to the
reference product of the innovator.
Accessibility of pertuzumab in India has remained a
significant challenge and only limited HER2-postive breast cancer patients are
able to use it in their treatment due to cost barriers. By bringing an
affordable pertuzumab biosimilar, backed by research, regulatory-compliant
manufacturing, and strong oncology distribution network, Alkem strives to
ensure scientific credibility and improved accessibility.
“Breast
cancer is the most common cancer among Indian women, and addressing its growing
burden requires treatments that are effective, accessible and affordable.
Oncology is a priority area for Alkem, and our efforts are focused on
developing treatment options that combine scientific excellence with wider
access. The launch of Pertuza reflects this commitment and further strengthens
our oncology portfolio. Alkem aims to make this critical therapy available to thousands
of women each year who would otherwise be excluded,” said Dr. Vikas
Gupta, Chief Executive Officer, Alkem.
Alkem has a growing portfolio of oncology drugs with
key products being cetuximab biosimilar, denosumab biosimilar, bevacizumab
biosimilar, and romiplostim biosimilar, among others.
,%20Navi%20Mumb.jpeg)
0 Comments